Brokerages Set Scholar Rock Holding Corporation (NASDAQ:SRRK) Target Price at $54.36

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have earned an average rating of “Buy” from the seventeen ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and four have assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $54.3571.

SRRK has been the topic of a number of research reports. Barclays increased their price objective on Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, March 3rd. BMO Capital Markets boosted their target price on shares of Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 4th. HC Wainwright restated a “buy” rating and set a $58.00 price target on shares of Scholar Rock in a research note on Tuesday, March 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Finally, UBS Group assumed coverage on shares of Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective for the company.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $45.43 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.95 and a quick ratio of 6.95. Scholar Rock has a one year low of $22.71 and a one year high of $49.82. The business’s 50-day moving average price is $45.15 and its two-hundred day moving average price is $40.19. The company has a market capitalization of $5.22 billion, a P/E ratio of -13.24 and a beta of 0.70.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. During the same period in the previous year, the company earned ($0.64) EPS. Analysts anticipate that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Scholar Rock

In other Scholar Rock news, CEO David Hallal sold 57,450 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $2,453,115.00. Following the transaction, the chief executive officer directly owned 1,541,645 shares in the company, valued at $65,828,241.50. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Vikas Sinha sold 16,755 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $715,438.50. Following the completion of the sale, the chief financial officer directly owned 583,245 shares of the company’s stock, valued at $24,904,561.50. This represents a 2.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 207,464 shares of company stock valued at $9,157,423. Insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc grew its holdings in Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Scholar Rock in the fourth quarter worth $30,000. Summit Securities Group LLC acquired a new stake in shares of Scholar Rock in the fourth quarter worth $31,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares during the period. Finally, Hilton Head Capital Partners LLC acquired a new position in Scholar Rock in the 4th quarter valued at $44,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).